Pragmatic Evaluation of Performance and Safety of the Anchorsure® Transvaginal Device for Surgical Treatment of Apical Prolapse in Women

Inclusion Criteria: * Women with pelvic organ prolapse with leading edge at or beyond the hymen as confirmed by the pelvic organ prolapse quantification system (POP-Q), i.e. Ba ≥ -1 cm for the anterior compartment, and/or Bp ≥ -1 cm for the posterior compartment, and/or C ≥ -1 cm for the apical compartment including recurrence. * Women due for POP surgery using the Anchorsure System® for apical prolapse suspension with or without concomitant native tissue repair, with or without concomitant hysterectomy and with or without concomitant sling for stress urinary incontinence. * All women who have not indicated any objection to participating in the study. * All women who have been correctly informed. Exclusion Criteria: * Patient taking part or having taken part in a device or drug interventional study within the last three months (except for VIGI-MESH national registry). * Patients due for pelvic organ prolapse repair without apical suspension or with anything other than native tissue repair and the Anchorsure System®. * Patients with uncontrolled diabetes mellitus. * Patients with active non-controlled or chronic gynaecologic or urinary tract infection and/or local tissue necrosis. * Patients with ongoing pelvic organ cancer (e.g. uterine, ovarian, bladder, cervix …). * Patients with a history of radiotherapy in the pelvic area. * Patients on therapy with immunosuppressive or immunomodulatory treatment within the previous month. * patients under ongoing oral anticoagulant therapy. * Patients with stage 0 and 1 pelvic organ prolapse at the time of surgery * Patients with a preoperative infection contraindicating the surgery